Advancement in Metabolic dysfunction-Associated SteatoHepatitis (MASH) treatment: the first FDA approved drug Published On 21 May 2024 In Biology Pharmacology R&D The FDA approves Madrigal Pharmaceuticals’ Rezdiffra for Metabolic dysfunction-Associated SteatoHepatitis (MASH), ... By Editorial Staff
